Clinical Trial Update: Abemaciclib, Palbociclib or Dalpiciclib Combined with Endocrine Therapy As First-line Treatment in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer

View source ↗

Summary

A clinical trial update for first-line treatment of HR-positive, HER2-negative unresectable or metastatic breast cancer testing abemaciclib, palbociclib, or dal…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Dalpiciclib (dalpiciclib)
• IBRANCE (PALBOCICLIB)
• VERZENIO (ABEMACICLIB)

Snippet

Sponsor: Fudan University | Conditions: Breast Cancer | Status: ACTIVE_NOT_RECRUITING